Prospects for cannabinoid therapies in basal ganglia disorders.

Key Findings:  The evidence reported so far supports that those cannabinoids having antioxidant properties and/or capability to activate CB2 receptors may represent promising therapeutic agents in HD and PD, thus deserving a prompt clinical evaluation.

Type of Study:  Meta-analysis

Study Result:  Positive

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC)

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB1, CB2

Ligands Studied:  Anti-inflammatory cytokines, Dopamine, GABA, Glutamate, Pro-inflammatory cytokines

Study Location(s):  Israel, Spain

Year of Pub:  2011

Link to study